TCT 2017: BIOTRONIK Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is ga…
Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is ga…
BIOTRONIK’s exclusive rate responsive technology, Closed Loop Stimulation (CLS) has shown to reduce fainting in pacemake…
Cardiology experts will present conclusive results from various BIOTRONIK studies at the European Society of Cardiology’…
BIOTRONIK Studies Highlight Pertinent Questions: Can We Avoid ICD Therapy? Do CRT Patients Benefit from Rate-Adaptive Pa…
BIOTRONIK, a leading manufacturer of cardio- and endovascular technology, presented 12-month results of the BIOFLOW-IV m…
Physicians presented encouraging interim data on the efficacy of BIOTRONIK’s dedicated lower limb intervention portfolio…
BIOTRONIK announced the presentation of data confirming the efficacy of the Pulsar-18* bare metal self-expanding stent (…
BIOTRONIK today presented users’ first experiences with Magmaris* during a symposium at TCT. The BIOSOLVE-II trial had p…
BIOTRONIK announced results establishing the Orsiro* hybrid drug-eluting stent (DES) as non-inferior to competing Resolu…
BIOTRONIK announced today the commercial launch of Solia S ProMRI®, with a 5.6 French lead body, the smallest MR conditi…